These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21133714)

  • 1. A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells.
    Vega MI; Baritaki S; Huerta-Yepez S; Martinez-Paniagua MA; Bonavida B
    Leuk Lymphoma; 2011 Jan; 52(1):108-21. PubMed ID: 21133714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs.
    Martinez-Paniagua MA; Vega MI; Huerta-Yepez S; Baritaki S; Vega GG; Hariharan K; Bonavida B
    Mol Cancer Ther; 2012 Mar; 11(3):572-81. PubMed ID: 22267549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis.
    Baritaki S; Militello L; Malaponte G; Spandidos DA; Salcedo M; Bonavida B
    Int J Oncol; 2011 Jun; 38(6):1683-94. PubMed ID: 21455568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
    Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
    Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
    Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
    Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis.
    Martínez-Paniagua MA; Baritaki S; Huerta-Yepez S; Ortiz-Navarrete VF; González-Bonilla C; Bonavida B; Vega MI
    Cell Cycle; 2011 Aug; 10(16):2792-805. PubMed ID: 21822052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1.
    Baritaki S; Huerta-Yepez S; Sakai T; Spandidos DA; Bonavida B
    Mol Cancer Ther; 2007 Apr; 6(4):1387-99. PubMed ID: 17431117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
    Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B
    J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.
    Bonavida B
    Oncogene; 2007 May; 26(25):3629-36. PubMed ID: 17530016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1.
    Huerta-Yepez S; Vega M; Escoto-Chavez SE; Murdock B; Sakai T; Baritaki S; Bonavida B
    Nitric Oxide; 2009 Feb; 20(1):39-52. PubMed ID: 18778787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation.
    Baritaki S; Katsman A; Chatterjee D; Yeung KC; Spandidos DA; Bonavida B
    J Immunol; 2007 Oct; 179(8):5441-53. PubMed ID: 17911631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
    Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively.
    Vega MI; Jazirehi AR; Huerta-Yepez S; Bonavida B
    J Immunol; 2005 Aug; 175(4):2174-83. PubMed ID: 16081784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis.
    Suzuki E; Umezawa K; Bonavida B
    Oncogene; 2007 Sep; 26(42):6184-93. PubMed ID: 17420722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
    Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
    Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate.
    Sieber S; Gdynia G; Roth W; Bonavida B; Efferth T
    Int J Oncol; 2009 Jul; 35(1):149-58. PubMed ID: 19513562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
    J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.
    Vega MI; Martínez-Paniagua M; Huerta-Yepez S; González-Bonilla C; Uematsu N; Bonavida B
    Int J Oncol; 2009 Dec; 35(6):1289-96. PubMed ID: 19885551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.